Bicycle Therapeutics plc: Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression

Completed Phase I dose escalation; results expected in 3Q22 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,United States ,David Borah ,Sarah Sutton ,Kevin Lee ,Exchange Commission ,Nasdaq ,Bicycle Toxin Conjugate ,Chief Executive Officer ,Cancer Research United Kingdom Centre ,Private Securities Litigation Reform Act ,Quarterly Report ,Capital Markets Investor Relations ,Bicycle ,Herapeutics ,Nnounces ,First ,Patient ,Hosed ,Expansion ,Cohorts ,Hase ,Trial ,Toxin ,Conjugate ,T5528 ,Patients ,Dvanced ,Olid ,Rumors ,Ssociated ,Pha2 ,Expression ,